室管膜瘤治疗市场：按药物类型、疾病类型、分销渠道、地区 - 规模、份额、展望、机会分析，2022-2030 年

室管膜瘤是一种罕见的脑肿瘤，称为神经胶质瘤。 它起源于大脑和脊髓中的室管膜细胞。 室管膜瘤可发生于儿童和成人。 一种柔软的灰色或红色肿瘤，可能包含囊肿或矿物质钙化。 室管膜瘤的症状取决于肿瘤是在大脑中还是在脊髓中。 室管膜瘤有四种主要类型：亚独立性室管膜瘤、粘液乳头状室管膜瘤、间变性室管膜瘤和经典室管膜瘤。 室管膜瘤的症状与肿瘤的位置和大小有关。 在婴儿中，首发症状之一是头部变大。 随着肿瘤的增大，可出现烦躁、失眠、呕吐等症状。 噁心、呕吐和头痛是年龄较大的儿童和成人最常见的症状。

市场动态

全球室管膜瘤治疗市场的主要参与者正专注于增加室管膜瘤的研究和开发，预计这将在预测期内推动市场增长。 例如，2022 年 4 月，儿科脑肿瘤联合会启动了一项针对复发性髓母细胞瘤和室管膜瘤儿科患者的基于静脉注射 ombutamab 的放射免疫疗法的 2 期试验。 该试验计划于 2030 年 7 月 30 日结束。 此外，增加室管膜瘤的研究经费预计将在预测期内推动全球室管膜瘤药物市场的增长。 例如，2021 年 11 月，由耶鲁大学公共卫生学院的研究人员领导的一组科学家着手研究主要影响年轻人的低级神经胶质瘤（生长缓慢但恶性的脑肿瘤）的分子进化。它有获得了 1300 万美元的资助。

本研究的主要特点

• 本报告对全球室管膜瘤治疗市场进行了深入分析，包括以 2021 年为基准年的预测期（2022-2030 年）的市场规模（百万美元）和復合年增长率 (CAGR%).
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 我们根据公司概况、产品组合、主要亮点、财务业绩和战略等参数对全球室管膜瘤治疗市场的主要参与者进行了概况分析。
• 本研究涵盖的主要公司包括 Fera Pharmaceuticals、Pfizer、Novartis AG、Merck KGaA、Baxter、Cipla Limited、Zydus Cadila、Lupin Pharmaceuticals, Inc.、UCB, Inc.、APOTEX INC 和 Moleculin Biotech., Inc. .
• 这份报告中的见解将使企业营销人员和高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 《全球室管膜瘤治疗市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球室管膜瘤治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按药物类型
  • 按疾病类型划分的市场概况
  • 市场概况：按销售渠道
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 商机
• 影响分析
• 监管场景
• 市场趋势
• 主要发展状况
• 流行病学
• 害虫分析
• 合作伙伴关係和收购
• 搬运工分析
• 管道分析

第 4 章室管膜瘤药物的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

• 经济影响
• 对供需的影响
• COVID-19 影响评估

第 5 章全球室管膜瘤药物市场，按药物类型，2017-2030

• 肾上腺皮质类固醇
• 抗惊厥药
• 其他

第 6 章全球室管膜瘤药物市场：按疾病类型分类，2017-2030

• 室管膜下瘤
• 黏液乳头状室管膜瘤
• 间变性室管膜瘤
• 经典室管膜瘤

第 7 章室管膜瘤药物全球市场：分销渠道，2017-2030

• 医院药房
• 零售药房
• 在线药店

第 8 章全球室管膜瘤药物市场：地区，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 法国
• 意大利
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 澳大利亚
• 韩国
• 东盟
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第9章竞争格局

• 热图分析
• 市场份额分析
  • Fera Pharmaceuticals.
  • Pfizer
  • Novartis AG
  • Merck KGaA,
  • Baxter
  • Cipla Limited
  • Zydus Cadila
  • Lupin Pharmaceuticals, Inc.
  • UCB, Inc.
  • APOTEX INC
  • Moleculin Biotech, Inc.,

第 10 章

• 调查方法介绍
• 关于出版商

Ependymoma is a rare type of brain tumour called a glioma. It starts from ependymal cells in the brain or spinal cord. Ependymomas can develop in children and adults. They are soft, grayish, or red tumors which may contain cysts or mineral calcifications. Symptoms of ependymomas depend on whether the tumor is in the brain or the spinal cord. These tumors are divided into four major types, subependymoma, myxopapillary ependymoma, anaplastic ependymoma and classic ependymomas. Symptoms of an ependymoma are related to the location and size of the tumor. In infants, increased head size may be one of the first symptoms. Irritability, sleeplessness, and vomiting may develop as the tumor grows. In older children and adults, nausea, vomiting, and headache are the most common symptoms

Market Dynamics

Key players operating in the global ependymoma drug market are focusing on increasing research and development for ependymoma which is expected to drive the market growth during the forecast period. For instance, in April 2022, Pediatric Brain Tumor Consortium initiated Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma. The study is estimated to be completed in July 30, 2030. Moreover, increasing research funding for ependymoma is expected to propel growth of the global ependymoma drug market over the forecast period. For instance, in November 2021, a team of scientists led by researchers at the Yale School of Public Health had received a US $13 million grant to investigate the molecular evolution of lower grade gliomas, slow growing but malignant brain tumors that primarily affect young adults.

Key features of the study:

• This report provides an in-depth analysis of the global ependymoma drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ependymoma drug market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ependymoma drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ependymoma drug market

Detailed Segmentation:

• Global Ependymoma Drug Market, By Drug Type:
  • Corticosteroids
  • Antiseizure Agents
  • Others
• Global Ependymoma Drug Market, By Disease Type :
  • Subependymoma
  • Myxopapillary Ependymoma
  • Anaplastic Ependymoma
  • Classic Ependymomas
• Global Ependymoma Drug Market, By Distribution Channel :
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global Ependymoma Drug Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Fera Pharmaceuticals *
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer .
  • Novartis AG
  • Merck KGaA
  • Baxter
  • Cipla Limited
  • Zydus Cadila
  • Lupin Pharmaceuticals, Inc.,
  • UCB, Inc.,
  • APOTEX INC,
  • Moleculin Biotech, Inc

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channels
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunity
• Impact Analysis
• Regulatory Scenario
• Market Trends
• Key Developments
• Epidemiology
• PEST Analysis
• Collaboration and Acquisition
• Porters Analysis
• Pipeline Analysis

4. Global Ependymoma Drug Market- Impact of Coronavirus (COVID-19) Pandemic

• Economic Impact
• Impact on Demand and Supply
• COVID-19 Impact Assessments

5. Global Ependymoma Drug Market, By Drug Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Antiseizure Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Others
  • Introduction dna
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Ependymoma Drug Market, By Disease Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Subependymoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Myxopapillary Ependymoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Anaplastic Ependymoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Classic Ependymomas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

7. Global Ependymoma Drug Market, By Distribution Channel, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Ependymoma Drug Market, By Region, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
  • Fera Pharmaceuticals.*
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Pfizer
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck KGaA,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Baxter
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Cipla Limited
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Zydus Cadila
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Lupin Pharmaceuticals, Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • UCB, Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • APOTEX INC
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Moleculin Biotech, Inc.,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies

10. Section

• Research Methodology
• About us